Hepatitis C Infection and People Who Inject Drugs is a new resource for medical providers aimed at improving the health of people who inject drugs.
MK3, a fixed-dose combination of three direct-acting antivirals (DAAs) with different mechanisms of action, provided cure rates exceeding 95% in patients with hepatitis C genotypes 1, 2, or 3.
Every 30% increase of time taking a statin yielded a one-third lower risk of cirrhosis in HIV/HCV-coinfected male veterans who did not already have advanced liver disease.
Despite the diversity of new direct-acting antivirals (DAAs), a tiny number of patients are still left behind. Nancy Reau, M.D., presented a summary of soon-to-be-approved drugs that should work for these tough-to-treat patients.
State Medicaid Programs Ease Illegal Restrictions on Hepatitis C Medications, but More Progress Needed
While restrictions for obtaining hepatitis C drugs through Medicaid programs vary state by state, restrictions eased somewhat across the country from 2014 to 2016, according to data presented at the Liver Meeting 2016.
Over one million people in low- and middle-income countries have been treated with a revolutionary new cure for hepatitis C since its introduction two years ago. However, high prices remain a major barrier to access.
Routine hepatitis C (HCV) antibody testing of men who have sex with men (MSM) at an Amsterdam sexually transmitted infection (STI) clinic yielded additional and earlier HCV diagnoses in HIV-positive men attending an HIV clinic.
"Jail and prison officials often say the high cost of HCV management and treatment forces them to create guidelines so those with the greatest degree disease progression get care first," Matthew Zielske writes. "Such actions lead to rationing which r...
A study of state departments of correction concludes that prisoners are not receiving vital hepatitis C treatment due to extremely high drug costs.
U.S. Liver Organization Recommends That People With Hepatitis C Be Tested for Hepatitis B Before Starting Antiviral Therapy
The American Association for the Study of Liver Diseases has issued a statement saying all patients beginning hepatitis C treatment using direct-acting antivirals should be assessed for hepatitis B to avoid potential "mild to severe liver injury that...